‘Time Toxicity’ and its Effect on Patients With Stage 4 Melanoma

Commentary
Video

The notion of ‘time toxicity’ causes patients with stage 4 melanoma to have less available time in their everyday lives because of appointments and treatments.

Patients with stage 4 melanoma experience more time toxicity, as they are expected to attend more in-person doctor visits for optimal survival, according to an expert.

Time toxicity, defined by Dr. Timothy Hanna, is an unintended effect in a person’s life, particularly with their time.

Hanna is a radiation oncologist and health services researcher at Queen’s University in Kingston, Ontario, Canada, who specializes in skin cancer treatments, and co-authored a study that was published on JAMA Network.

His research determined that patients with stage 4 melanoma experience more time toxicity because of the amount of time taken away from their everyday life to attend in-person appointments to receive procedures, such as biopsies and surgeries, and drug therapies and radiation.

“The time that (patients) could spend with family, fishing, going to restaurants and enjoying their everyday life is taken away from them to some degree because of the time burden and (doctor) visits that are required in order to gain these survival benefits from the treatments,” Hanna explained in an interview with CURE®.

Hanna and co-authors of the study found that patients with stage 4 melanoma were “spending more than one day per week on health care-related contacts.”

LEARN MORE: Types of Skin Cancer and Their Treatments

“So that’s really important. I think (it’s) valuable information for people who are diagnosed with advanced stage 4 melanoma to know about,” said Hanna. “It’s nice to know that with these new drugs, the chances of living longer, is much better. So, there is this time investment, but thankfully, that time investment hasn’t really gotten any larger compared to how it used to be. So, for that same investment, we’re getting essentially a greater return because of the possibility of longer survival.”

Transcript:

New cancer treatments are often accompanied by many health care visits, you know, we need visits for imaging for seeing the specialist for blood tests. We need visits for medical procedures, like biopsies, surgeries, visits for these expensive new drug therapies, radiation and this can take up a lot of a person's time.

Now, if we're talking about a therapy where this is a lifesaving therapy and it's an earlier stage disease, investing a few months of your time, in order for your life to be saved, would always be worthwhile, you could say. But, when we start thinking about people with more advanced cancers, for example, those with stage 4 disease, such as stage 4 melanoma, in some cases, they may only have a few months or years to live. And so, when we start to think about the time burden that all of these visits placed upon them, this is something that is now called in by many people time toxicity, meaning that this is an unintended effect on a person's time that has, in the patient's perspective, often ill effects. So, the time that they could spend with family, fishing, going to restaurants and enjoying their everyday life, is taken away to some degree because of the time burden and the visits that are required in order to gain these survival benefits from the treatment.

So, what is called time toxicity doesn't specifically affect someone's survival, but it does impact the usefulness of the time that someone might have left. So, if you only had say, three months of life left and half of that was spent on the visits to hospital, those gains and survival from these new expensive drugs might not be, from the patient perspective, worth it. They might decide it's totally worth it. But the information that we can gather and describe for patients under this concept called time toxicity provides information that can help patients and their families decide on the value that they place on the benefits of treatment.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content